TY - JOUR
T1 - Prosthetic valve endocarditis
T2 - Literally a growing concern following transcatheter aortic valve replacement
AU - Goldsweig, Andrew M.
AU - Baron, Suzanne J.
N1 - Funding Information:
Dr. Goldsweig reports grant support from the National Institute of General Medical Sciences, 1U54GM115458, and the UNMC Center for Heart and Vascular Research. Dr. Baron reports consulting for Boston Scientific Corp, Abiomed, Abbott, Edwards, and Mitra Labs and research support from Abiomed and Boston Scientific Corp. The content is solely the responsibility of the authors and does not necessarily represent the official views of their employers or research supporters.
Publisher Copyright:
© 2022 Wiley Periodicals LLC
PY - 2022/2/15
Y1 - 2022/2/15
N2 - Prosthetic valve endocarditis (PVE) following transcatheter aortic valve replacement (TAVR) in low surgical risk patients is uncommon, occurring in 11 of 396 patients (2.8%) in the study by Medranda et al., but associated with high morbidity (6 of 11 with embolic strokes [55%]) and mortality (2 of 11 [18%]). As TAVR volumes increase, especially in low surgical risk patients, whose long-term outcomes are generally excellent, PVE will become an increasingly important concern. Future research is needed to identify optimal strategies for prevention, diagnosis, and treatment of PVE associated with TAVR.
AB - Prosthetic valve endocarditis (PVE) following transcatheter aortic valve replacement (TAVR) in low surgical risk patients is uncommon, occurring in 11 of 396 patients (2.8%) in the study by Medranda et al., but associated with high morbidity (6 of 11 with embolic strokes [55%]) and mortality (2 of 11 [18%]). As TAVR volumes increase, especially in low surgical risk patients, whose long-term outcomes are generally excellent, PVE will become an increasingly important concern. Future research is needed to identify optimal strategies for prevention, diagnosis, and treatment of PVE associated with TAVR.
KW - AVD – aortic valve disease
KW - AVDP – aortic valve disease percutaneous intervention
KW - ENDO – endocarditis
KW - RISK– risk stratification
KW - TVI – transcatheter valve implantation
UR - http://www.scopus.com/inward/record.url?scp=85125595009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125595009&partnerID=8YFLogxK
U2 - 10.1002/ccd.30126
DO - 10.1002/ccd.30126
M3 - Editorial
C2 - 35235689
AN - SCOPUS:85125595009
SN - 1522-1946
VL - 99
SP - 904
EP - 905
JO - Catheterization and Cardiovascular Interventions
JF - Catheterization and Cardiovascular Interventions
IS - 3
ER -